Imatinib Onkogen (Imatinib)

Imatinib is a targeted therapy that effectively inhibits the BCR‑ABL tyrosine kinase pathway, used in specific hematologic and solid tumours.

• Chronic myeloid leukemia (CML): inhibits BCR‑ABL activity, leading to decreased proliferation of leukemic cells and prolonged disease control.
• Gastrointestinal stromal tumor (GIST): blocks KIT or PDGFRA signaling, resulting in reduced tumor growth and disease stabilization.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): suppresses BCR‑ABL driven leukemic blasts, supporting remission when used with standard chemotherapy.

• Imatinib binds competitively to the ATP‑binding pocket of the BCR‑ABL fusion protein as well as to the KIT and PDGFRA tyrosine kinases. By occupying this site, it prevents phosphorylation of downstream substrates, halting signal transduction that drives cell proliferation and survival. The inhibition is selective, sparing most normal kinases and thereby reducing off‑target effects. This blockade leads to apoptosis of malignant cells dependent on these pathways.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild to moderate stomach upset that may affect appetite.
• Edema: swelling of hands, feet, or face, often peripheral.
• Muscle cramps: intermittent painful tightening of muscles, especially in the limbs.
• Fatigue: general tiredness or lack of energy impacting daily activities.
• Diarrhea: loose stools that may lead to dehydration if persistent.
• Rash: skin redness or itching that can appear on trunk or limbs.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or clinically significant liver injury.
• Severe neutropenia: marked reduction in white blood cells increasing infection risk.
• Cardiac failure: signs of reduced heart function such as shortness of breath or edema.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Pulmonary hypertension: increased pressure in lung arteries causing breathlessness.
• Tumor lysis syndrome: rapid tumor cell breakdown leading to metabolic disturbances.

When prescribing Imatinib, clinicians should observe several safety precautions to minimise risks.

• Monitor blood counts: regular CBC testing to detect neutropenia or anemia.
• Assess liver function: periodic liver enzyme tests for hepatotoxicity.
• Evaluate cardiac status: baseline and periodic ECG or echocardiogram for heart failure.
• Avoid use in patients with known hypersensitivity: discontinue if allergic reactions occur.
• Use caution in pregnancy: potential risks are unknown; weigh benefits against risks.
• Store at room temperature: keep below 25 °C in original packaging, protect from moisture.

Imatinib interacts with several medicines that can alter its plasma levels or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise Imatinib concentrations and toxicity.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower Imatinib levels, reducing efficacy.
• Antacids containing aluminum or magnesium: can reduce absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• Warfarin: Imatinib may enhance anticoagulant effect, requiring INR monitoring.
• Diuretics (e.g., furosemide): may increase risk of electrolyte disturbances.
• QT‑prolonging agents (e.g., sotalol): combined use may heighten arrhythmia risk.
• Proton pump inhibitors: may modestly affect drug exposure, monitor clinical response.